Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
200 participants
INTERVENTIONAL
2019-06-17
2019-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Sedation Strategies for Diagnostic Bronchoscopy
NCT03406533
Dexmedetomidine for Sedation Undergoing Bronchoscopy
NCT04169685
Randomized Study With Midazolam for Sedation in Flexible Bronchoscopy
NCT01038882
Sedation During Bronchoscopy:Dexmedetomidine vs Alfentanil
NCT01805726
Alternative Sedation During Bronchoscopy
NCT01158820
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
F
Sedated with intravenous midazolam (0.03mg/kg) and fentanyl (1μg/kg) for induction and maintenance
Midazolam
Midazolam is used as a common medication for sedation in all groups.
Fentanyl
Fentanyl is another opioid drug used for analgesia to prevent bronchoscopy induced cough.
DR
Sedated with intravenous midazolam (0.03mg/kg), dexmedetomidine (0.5-1μg/kg for induction+0.5-0.7μg/kg/h for maintenance) and remifentanil (plasma concentration 2.0-2.5ng/ml) for induction and maintenance
Midazolam
Midazolam is used as a common medication for sedation in all groups.
Dexmedetomidine
Dexmedetomidine is used for sedation in bronchoscopy with less impact on respiration.
Remifentanil
Remifentanil is used for analgesia to prevent bronchoscopy induced cough.
DF
Sedated with intravenous midazolam (0.03mg/kg), dexmedetomidine (0.5-1μg/kg for induction+0.5-0.7μg/kg/h for maintenance) and fentanyl (1μg/kg) for induction and maintenance
Midazolam
Midazolam is used as a common medication for sedation in all groups.
Fentanyl
Fentanyl is another opioid drug used for analgesia to prevent bronchoscopy induced cough.
Dexmedetomidine
Dexmedetomidine is used for sedation in bronchoscopy with less impact on respiration.
PR
Sedated with intravenous midazolam (0.03mg/kg), propofol (plasma concentration 1.0-2.0ng/ml) and remifentanil (plasma concentration 2.0-2.5ng/ml) for induction and maintenance
Midazolam
Midazolam is used as a common medication for sedation in all groups.
Remifentanil
Remifentanil is used for analgesia to prevent bronchoscopy induced cough.
Propofol
Propofol is used for sedation with high efficacy but more side effect on respiration than dexmedetomidine.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Midazolam
Midazolam is used as a common medication for sedation in all groups.
Fentanyl
Fentanyl is another opioid drug used for analgesia to prevent bronchoscopy induced cough.
Dexmedetomidine
Dexmedetomidine is used for sedation in bronchoscopy with less impact on respiration.
Remifentanil
Remifentanil is used for analgesia to prevent bronchoscopy induced cough.
Propofol
Propofol is used for sedation with high efficacy but more side effect on respiration than dexmedetomidine.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adult patients aged 18 to 65 years
* American Society of Anesthesiologists (ASA) Physical Status Classification I-II
* BMI 18.5-25kg/m2
* Subjects provide informed consent
Exclusion Criteria
* Coagulation disorder
* Repeat bronchoscopy (more than 3 times)
* Severe liver and renal dysfunction
* Cardiovascular and cerebrovascular diseases
* Pregnancy
* Chronic opioid user
* Drug abusers or addicts
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Zhongshan Hospital
OTHER
Ruijin Hospital
OTHER
Shanghai Pulmonary Hospital, Shanghai, China
OTHER
Changhai Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jia-feng Wang
Clinical Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Faculty of Anesthesiology, Changhai Hospital
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SED-DFB2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.